<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37717649</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-3511</ISSN><JournalIssue CitedMedium="Internet"><Volume>136</Volume><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</Title><ISOAbbreviation>Int J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Vaccination after developing long COVID: Impact on clinical presentation, viral persistence, and immune responses.</ArticleTitle><Pagination><StartPage>136</StartPage><EndPage>145</EndPage><MedlinePgn>136-145</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijid.2023.09.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1201-9712(23)00720-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Vaccination protects against severe COVID-19 manifestations. For those with post-COVID-19 conditions (PCC) or long COVID, the impact of COVID-19 vaccination on the evolution of symptoms, immune responses, and viral persistence is unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this prospective observational cohort study, we evaluated the number of PCC symptoms, affected organ systems, and psychological well-being scores before and after patients with PCC received COVID-19 vaccination. We simultaneously evaluated biomarkers of systemic inflammation and levels of plasma cytokines/chemokines. We measured plasma and intracellular levels of SARS-CoV-2 antigens, and immunoreactivity to SARS-CoV-2 antigens in blood.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">COVID-19 vaccination was associated with decreases in number of PCC symptoms (pre-vaccination: 6.56 &#xb1; 3.1 vs post-vaccination: 3.92 &#xb1; 4.02; P&#xa0;&lt;0.001) and affected organ systems (pre-vaccination: 3.19 &#xb1; 1.04 vs post-vaccination: 1.89 &#xb1; 1.12; P&#xa0;&lt;0.001), and increases in World Health Organization (WHO)-5 Well-Being Index Scores (pre-vaccination: 42.67 &#xb1; 22.76 vs post-vaccination: 56.15 &#xb1; 22.83; P&#xa0;&lt;0.001). Patients with PCC also had significantly decreased levels of several pro-inflammatory plasma cytokines/chemokines after COVID-19 vaccination including sCD40L, GRO-&#x237a;, macrophage inflammatory protein (MIP)-1&#x237a;, interleukin (IL)-12p40, G-colony stimulating factor (CSF), M-CSF, IL-1&#x3b2;, and stem cell factor (SCF). PCC participants presented a certain level of immunoreactivity toward SARS-CoV-2, that was boosted with vaccination. SARS-CoV-2 S1 antigen persisted in the blood of PCC participants, mostly in non-classical monocytes, regardless of participants receiving vaccination.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study shows higher pro-inflammatory responses associated with PCC symptoms and brings forward a possible role for vaccination in mitigating PCC symptoms by decreasing systemic inflammation. We also observed persistence of viral products independent of vaccination that could be involved in perpetuating inflammation through non-classical monocytes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nayyerabadi</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Inflammation, Immunity and Infectious Diseases, Montreal Clinical Research Institute (IRCM), Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fourcade</LastName><ForeName>Lyvia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Inflammation, Immunity and Infectious Diseases, Montreal Clinical Research Institute (IRCM), Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joshi</LastName><ForeName>Swarali A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Center for Inflammation, Immunity and Infectious Diseases, Montreal Clinical Research Institute (IRCM), Montreal, QC, Canada; Center for Commercialization of Regenerative Medicine (CCRM), Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandrasekaran</LastName><ForeName>Prabha</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>eHealth and Informatics, LLC., Rockville, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chakravarti</LastName><ForeName>Arpita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Infectious Diseases and Immunology, Universit&#xe9; de Montr&#xe9;al, Montreal, QC, Canada; Department of Infectious Diseases and Medical Microbiology, Centre Hospitalier de l'Universit&#xe9; de Montr&#xe9;al (CHUM), Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mass&#xe9;</LastName><ForeName>Chantal</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Inflammation, Immunity and Infectious Diseases, Montreal Clinical Research Institute (IRCM), Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Marie-Lorna</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Center for Inflammation, Immunity and Infectious Diseases, Montreal Clinical Research Institute (IRCM), Montreal, QC, Canada; Morphocell Technologies Inc., Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houle</LastName><ForeName>Joanie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Inflammation, Immunity and Infectious Diseases, Montreal Clinical Research Institute (IRCM), Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boubekeur</LastName><ForeName>Amina M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Center for Inflammation, Immunity and Infectious Diseases, Montreal Clinical Research Institute (IRCM), Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DuSablon</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Inflammation, Immunity and Infectious Diseases, Montreal Clinical Research Institute (IRCM), Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boudreau</LastName><ForeName>Val&#xe9;rie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Center for Cardiometabolic Health, Montreal Clinical Research Institute (IRCM), Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bovan</LastName><ForeName>Danijela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Cardiometabolic Health, Montreal Clinical Research Institute (IRCM), Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Darbinian</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Inflammation, Immunity and Infectious Diseases, Montreal Clinical Research Institute (IRCM), Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coleman</LastName><ForeName>Emilia A&#xef;sha</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Center for Inflammation, Immunity and Infectious Diseases, Montreal Clinical Research Institute (IRCM), Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vinci</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Inflammation, Immunity and Infectious Diseases, Montreal Clinical Research Institute (IRCM), Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Routy</LastName><ForeName>Jean-Pierre</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Medicine, McGill University Health Center (MUHC), Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xe9;tu</LastName><ForeName>Pierre-Olivier</ForeName><Initials>PO</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Centre Hospitalier de l'Universit&#xe9; de Montr&#xe9;al (CHUM), Montreal, QC, Canada; Centre de Recherche du Centre Hospitalier de l'Universit&#xe9; de Montr&#xe9;al (CRCHUM), Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poudrier</LastName><ForeName>Johanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Inflammation, Immunity and Infectious Diseases, Montreal Clinical Research Institute (IRCM), Montreal, QC, Canada; Department of Microbiology, Infectious Diseases and Immunology, Universit&#xe9; de Montr&#xe9;al, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falcone</LastName><ForeName>Emilia Liana</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Center for Inflammation, Immunity and Infectious Diseases, Montreal Clinical Research Institute (IRCM), Montreal, QC, Canada; Department of Microbiology, Infectious Diseases and Immunology, Universit&#xe9; de Montr&#xe9;al, Montreal, QC, Canada; Department of Infectious Diseases and Medical Microbiology, Centre Hospitalier de l'Universit&#xe9; de Montr&#xe9;al (CHUM), Montreal, QC, Canada; Department of Medicine, Universit&#xe9; de Montr&#xe9;al, Montreal, QC, Canada. Electronic address: emilia.falcone@ircm.qc.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Int J Infect Dis</MedlineTA><NlmUniqueID>9610933</NlmUniqueID><ISSNLinking>1201-9712</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018925">Chemokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007109" MajorTopicYN="N">Immunity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018925" MajorTopicYN="N">Chemokines</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Post-COVID-19 conditions (PCC)</Keyword><Keyword MajorTopicYN="N">Post-acute sequelae of COVID-19 (PASC)</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword><Keyword MajorTopicYN="N">Viral persistence</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest PC is employed by eHealth and Informatics, LLC; SAJ and MLP were employed at IRCM when this study was completed but are currently employed at the Center for Commercialization of Regenerative Medicine and Morphocell Technologies Inc. respectively. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>18</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>17</Day><Hour>19</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37717649</ArticleId><ArticleId IdType="doi">10.1016/j.ijid.2023.09.006</ArticleId><ArticleId IdType="pii">S1201-9712(23)00720-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>